العربيةStart a conversationContact
Insights

Regulatory Brief · Healthcare & Life Sciences · 10 November 2026

EDE Circular 46/2026 does not ban clinic peptides. It recalls what was bought outside the licensed chain, and the inventory due on 5 December shows which a clinic did.

Emirates Drug Establishment Circular 46/2026, relayed by DHA on 6 November 2026, recalls every peptide product imported, compounded or marketed without EDE approval and bans compounding from research-grade material. It also sets the lawful route: annex-listed pharmaceutical-grade raw material, imported by a licensed warehouse and compounded patient by patient in a licensed pharmacy. DHA wants each facility's peptide inventory by 5 December 2026. Exosome and PDRN products have no such route: DoH Circulars 185/2026 and 211/2026 stop their use and send the stock back to the supplier. For an aesthetics or wellness clinic, the molecule no longer settles the question. The invoice does.

The 30-second read

What a board member needs before the next meeting on this.

  1. Exosomes and PDRN are stopped. DoH Circular 185/2026 covers all products and lots and bars their clinical use in the UAE. Circular 211/2026 sends the stock back to the supplier unless a product holds an EDE marketing authorisation.
  2. Peptides face a sourcing rule, not a ban. EDE Circular 46/2026 recalls peptide products bought or compounded without EDE approval, and keeps a route for annex-listed molecules compounded patient by patient in a licensed pharmacy.
  3. The molecule list does not clear the stock. BPC-157 in the annex does not make a research-grade vial compliant. Non-compliant stock is quarantined and cannot return to use without EDE's written approval.
  4. The 5 December inventory is a disclosure. DHA wants regulatory status, source and purpose for every covered product, and will check them on inspection. What a clinic files now is the record a buyer will read later.
Applies to Owners and medical directors of DHA- and DoH-licensed aesthetic, dermatology, wellness and longevity clinics, the pharmacies that compound for them, and buyers running diligence on any of them

On 5 November 2026 the Emirates Drug Establishment issued Circular No. (46/2026), Guideline for Handling Peptide Products and Molecules, and the Dubai Health Authority sent it to every private facility the next day as CIR-2026-00000207 (EDE Circular 46/2026, relayed by DHA).

On 10 November DHA added its own procedures: stop using, prescribing and dispensing covered peptide products, quarantine them immediately, file an inventory of their regulatory status, sources and purposes of use by 5 December 2026, and review the records of patients already treated (DHA CIR-2026-00000208).

Abu Dhabi had already closed a second line: DoH Circular 185/2026 of 21 September stopped exosome and PDRN products, and Circular 211/2026 of 27 October sent the stock back to suppliers (DoH Circular 211/2026). Read quickly, that is three aesthetic and wellness revenue lines banned. Read in full, it is two lines stopped and a supply-chain test on the third.

How the three lines closed21 Sep 2026DoH 185/2026:exosomes and PDRN stopped27 Oct 2026DoH 211/2026:stock back to supplier5 Nov 2026EDE 46/2026:peptide recall, quarantine5 Dec 2026DHA peptideinventory due
01

Exosomes and PDRN have no route unless the product is registered

DoH Circular 185/2026 lists the affected products as all products and lots, from various or unidentified manufacturers, and states that they are not authorised for import, supply, sale, distribution or clinical use in the UAE, by injection, mesotherapy, Dermapen, microneedling or any other invasive procedure (DoH Circular 185/2026). Facilities had to stop use, quarantine stock and notify DoH with lot numbers, suppliers, invoices, records of use and the details of patients treated.

Circular 211/2026 then requires facilities to return the stock to the agent or distributor that supplied it, gives agents and importers 30 days from issue to collect, return or re-export it, which on our arithmetic runs to 26 November 2026, and states that any activity under Article 5 of Federal Decree-Law No. 38 of 2024 without a marketing authorisation is a violation (DoH Circular 211/2026).

Dubai relayed the matching EDE instructions, Circular 41/2026, on 7 October as CIR-2026-00000177 (DHA CIR-2026-00000177). For a clinic, this revenue line is gone unless a named product appears on EDE's Medical Products Register, and whether the supplier credits the returned stock is a commercial question the circulars do not answer.

02

The peptide circular is a sourcing rule, not a ban

Article 12.1 of EDE Circular 46/2026 recalls every peptide product and substance imported, compounded and marketed in the UAE without prior EDE approval, and Article 5.2 bans compounding from research-grade material or material of unknown origin (EDE Circular 46/2026). The same circular writes the lawful route.

Under Article 3.2 a licensed medical warehouse may import annex-listed, pharmaceutical-grade peptide raw material with prior EDE approval and supply it only to licensed compounding pharmacies, and under Article 5.1 injectable preparations may be compounded only by pharmacies licensed for sterile work.

The annex places BPC-157, TB-500, MOTS-c, KPV, Epitalon and Semax in Category 1, where the BPC-157 entry reads "single-API, patient-specific compounding", while noting that listing is not an automatic compounding authorisation. Retatrutide, cagrilintide, survodutide and thymosin beta-4 sit in Category 2, for authorised clinical studies only. Finished products holding a valid marketing authorisation fall outside the circular altogether.

Get the instruments that touch your licence, assessed, as they are issued. See Regulatory Watch

03

A buyer can get this wrong in both directions

A buyer who strips every dirham of peptide revenue from a clinic's earnings because peptides are "banned" over-discounts a line that can survive on a compliant supply chain. A buyer who keeps it because the molecules appear in the annex under-discounts a line that may have run on research-grade vials the circular has just recalled.

The annex settles the molecule; the invoice settles the source. Non-compliant stock is segregated and quarantined pending EDE's decision, and Article 7.2 bars its return to circulation without EDE's prior written approval (EDE Circular 46/2026). Article 9.2 also prohibits misleading claims about anti-ageing, cellular regeneration, immunity, energy, weight loss, muscle building or appearance, so the clinic's website and social posts belong in the same review.

04

The inventory is a disclosure the regulator will test

Article 12.3 gives establishments 30 days from issue to file their inventory and health authorities 15 days to forward it to EDE, and Articles 8.2 and 8.4 require compounding records traceable to the individual patient, kept for at least 5 years (EDE Circular 46/2026). DHA has set 5 December for Dubai facilities and says it will check compliance on upcoming inspection visits and review the lists with EDE (DHA CIR-2026-00000208).

When we checked DoH's circulars index on 19 November it carried no Abu Dhabi relay of EDE 46/2026, but Article 6.1(b) already routes Abu Dhabi facilities' lists through DoH. A list that matches the purchase ledger documents the exposure once. A list that does not becomes the subject of the next inspection.

05

What to pull on monday

An owner starts with the purchase invoices for every peptide, exosome and PDRN product bought in the last twelve months, matched to the supplier's licence and to EDE's register, because that match is what the DHA inventory asks for. Next comes the quarantine log with its cost, the supplier's written position on returned stock, and the list of patients treated with the follow-up DHA's circular requires.

A buyer asks for the same file plus the inventory as filed and any notification made under DoH Circular 185/2026, then splits the revenue line by product and source so the non-compliant share comes out of the earnings base and the compliant share is priced on its own supply chain. Keeping a facility's file current against each of these instruments is the work of our licence compliance retainer.

Before your next meeting

Four questions for a clinic board before the inspection

  1. Which of our peptide, exosome and PDRN revenue ran on registered products or a licensed compounding pharmacy, and which on anything else?
  2. What stock is in quarantine today, at what cost, and has the supplier agreed to take it back?
  3. Does the inventory we file by 5 December match our purchase invoices line by line?
  4. Which patients received these products, and is the follow-up the regulator requires recorded in their files?

This brief covers one instrument. The UAE healthcare regulatory tracker carries the full set — DoH, DHA, EDE and the other emirates — with what each one changes and when it takes effect.

Subscribe

The UAE healthcare regulatory briefing

What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.

One email a fortnight. Unsubscribe from any of them.

Engagement · Limited mandates

Choosing who advises you is itself a strategic decision.

We take a limited number of mandates at any time. If you are working a decision that needs independent counsel, start with a conversation.